The effectiveness of Highly Active Antiretroviral Therapy (HAART) has dramatically
changed the life expectancy of HIV-positive individuals. In last years, availability of new drugs and new classes of compounds led to increase
therapeutical choices for HIV patients. However, drug development in this field has been particularly rapid, and many issues related to long-term drug efficacy
and safety have still to be evaluated in the clinical setting. Moreover, focus on individual needs of HIV patients according to genetic, demographical and
clinical characteristics, suggested by a modern viewpoint of management of this longlife treatment, emphasizes the need of personalization and optimization
of the regimens. Under this viewpoint, knowledge of clinical pharmacology of antiretrovirals seems crucial for a modern approach to HIV therapy. A proper use of
drugs according to pharmacokinetic and pharmacodynamic properties can maximize the benefits and limit the drawbacks of the treatment.

AIM OF THE COURSE

The aim of the 3-day course is to address the clinicians to a correct management of antiretroviral therapy
based on a sound and comprehensive evaluation of the PK/PD characteristics of antiretroviral drugs. The course contents will consist of lectures, clinical case'
presentations, roundtables and plenary discussions in order to stimulate confrontation and improve understanding of critical issues.

DATES AND SCHEDULE

Turin, January 16-17-18

LANGUAGE

Official language of the Course is English.

TARGET AUDIENCE

Healthcare professionals who routinely take care of patients with HIV infection.